Study of Fuzheng Huayu tablets for fatty liver with cirrhosis
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests whether Fuzheng Huayu tablets can help people with fatty liver disease that has progressed to cirrhosis (scarring) that is still compensated (the liver is still working well). The goal is to see if the tablets slow or reverse liver damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have cirrhosis from fatty liver disease, confirmed by a special ultrasound (FibroScan) showing significant scarring, and your liver function tests are still good (Child-Pugh score less than 7).
- You do not have other liver diseases like hepatitis B or C, alcoholic liver disease, or autoimmune hepatitis.
- You have not had serious liver complications like bleeding in the stomach or esophagus, fluid in the belly needing treatment, or confusion due to liver problems.
- Your diabetes (if you have it) is controlled, with recent A1c level 9% or below, and your blood pressure is below 160/100 mmHg.
- You are not pregnant, breastfeeding, or planning pregnancy during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether Fuzheng Huayu tablets can help people who have had their first serious liver complication from hepatitis B-related cirrhosis avoid another one. It compares the tablets against a placebo (a dummy pill).
This trial tests a traditional Chinese herbal capsule (Linzhi Jianghuang Fufang) to treat non-alcoholic fatty liver disease—a buildup of fat in the liver not caused by alcohol. The study aims to see if this herbal treatment can safely reduce liver fat and improve metabolic health in people with early-stage fatty liver.
This study tests strategies to prevent cirrhosis in people with metabolic fatty liver disease and early to moderate liver scarring. It aims to find better ways to stop liver damage from getting worse.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This trial tests a new medication (efimosfermin alfa) for people with cirrhosis (liver scarring) caused by MASH, a type of fatty liver disease. It aims to see if the drug can help improve liver health.
This trial is testing a new ultrasound method to measure fat in the liver for people with metabolic fatty liver disease (MAFLD). It may help understand how well ultrasound can show liver fat compared to a liver biopsy or MRI.
Hear when a new Metabolic Dysfunction-associated Fatty Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.